Introduce a Lymphedema Prevention Program

Prevent Cancer-Related Lymphedema with Early Detection & Treatment Protocol

Lymphedema is one of the most feared consequences of cancer treatment among survivors¹. Early detection is critical to preventing lymphedema from becoming a chronic condition. SOZO^® with L-Dex^® helps healthcare professionals to identify at-risk patients early and intervene before lymphedema becomes irreversible.

Request a Demo

50% of patients who develop Lymphedema do so within 1 year after surgery²

Pat Whitworth, M.D. & Laura Lawson, M.D. Discuss Lymphedema Prevention

Dr. Pat Whitworth, Surgical Oncologist/Director and Dr. Laura Lawson, Breast Surgery Specialist, from the Nashville Breast Center share how their prevention protocol, aided by SOZO^® with L-Dex^®, has improved the treatment and prevention of lymphedema.

Bioimpedance Spectroscopy (BIS) Clinical Evidence

ImpediMed’s L-Dex^® technology has demonstrated real-world lymphedema-related outcomes as published in more than 140 peer-reviewed studies on over 17,000 patients. Our BIS technology is backed by over 400 peer-reviewed journal articles across a number of chronic diseases.

View Clinical Evidence

Direct Fluid Measurement (L-Dex^®) vs. Indirect Fluid Measurement

Traditional measurement tools are rudimentary and unreliable, or prohibitively expensive, complicated and invasive. Perometry, along with such low-tech tools like tape measure and water displacement, cannot measure an increase in fluid until actual swelling exists – the point where lymphedema may be irreversible.

SOZO^® measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz to provide a detailed fluid and tissue analysis.

Request a Demo

Immediately Access & Share Data Across Your Healthcare System

SOZO^® allows medical staff in hospitals and cancer clinics to test patients at the point of care and immediately share that information with oncologists and nurse practitioners.

Request a Demo

Guidelines for Lymphedema Prevention

Test. Trigger. Treat.^TM
While it is not possible to predict which patients will develop lymphedema, the L-Dex^® score was shown to detect the accumulation of fluid due to lymphedema early enough to treat and prevent progression⁵.

Test

Set an L-Dex^® Baseline & Initiate Periodic Testing After Surgery

Once a patient has been diagnosed with breast cancer, melanoma, or pelvic area cancers, they will be tested by a staff member to record a baseline L-Dex^®score. After cancer surgery, it is recommended that patients get tested every 3 months for the first 3 years, every 6 months for years 4 and 5, and annually thereafter⁶.

Trigger

Evaluate Increases 6.5 Above L-Dex^® Baseline

Clinical evidence supports that an elevated L-Dex^® score of 6.5 or more from the baseline serves as a “trigger” to indicate that the patient should be evaluated and treatment intervention should begin⁵.

Treat

Apply Treatment Protocol to Reduce Lymphedema Progression

Treatment for patients diagnosed with early lymphedema, including standard compression garments worn at home for 4 weeks, 12 hours per day, has been shown to reduce the progression of lymphedema by 95% in breast cancer patients⁵.

SOZO^® with L-Dex^® Helps Detect Lymphedema at the Subclinical Level

Bioimpedance spectroscopy (BIS) is the only reliable, non-invasive tool that can accurately detect accumulation of fluid due to subclinical lymphedema. In less than 30 seconds, medical staff can record an L-Dex^® score or fluid status and tissue composition using SOZO^®.